Intensity Therapeutics Inc.

11/17/2024 | Press release | Distributed by Public on 11/18/2024 13:36

INVINCIBLE 3 STUDY: A MULTICENTER, RANDOMIZED, PHASE 3 STUDY OF INTRATUMORAL INT230 6 COMPARED TO STANDARD OF CARE THERAPY IN SELECTED METASTATIC SOFT TISSUE SARCOMAS